Apoptotic Myeloid Marker Antibody (BOB93): sc-130294

Apoptotic Myeloid Marker Antibody (BOB93) is a mouse monoclonal IgG1 kappa light chain antibody that detects the Apoptotic Myeloid Marker protein of human origin by western blotting (WB) and flow cytometry (FCM). Anti-Apoptotic Myeloid Marker antibody (BOB93) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates, providing versatility for different experimental needs. Apoptotic Myeloid Marker protein plays a crucial role in the identification and characterization of apoptotic cells, which is essential for understanding various physiological and pathological processes, including immune responses and tissue homeostasis. Apoptotic Myeloid Marker protein is primarily located on the surface of myeloid cells, which originate from the bone marrow and are integral to the immune system. Apoptotic Myeloid Marker (BOB93) antibody enables researchers to track apoptotic myeloid cells, providing insights into conditions such as inflammation and cancer, where apoptosis is often dysregulated. Anti-Apoptotic Myeloid Marker antibody (BOB93) helps scientists gain a deeper understanding of myeloid cell dynamics and their implications in disease progression and treatment responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Apoptotic Myeloid Marker Antibody (BOB93) References:

1. Mast cell and myeloid marker expression during early in vitro mast cell differentiation from human peripheral blood mononuclear cells.  |  Welker, P., et al. 2000. J Invest Dermatol. 114: 44-50. PMID: 10620114
2. Myeloid marker expression on antiviral CD8+ T cells following an acute virus infection.  |  Lin, Y., et al. 2003. Eur J Immunol. 33: 2736-43. PMID: 14515257
3. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells.  |  Fujiyama, S., et al. 2003. Circ Res. 93: 980-9. PMID: 14525810
4. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells.  |  Viemann, D., et al. 2005. Blood. 105: 2955-62. PMID: 15598812
5. Myeloid lineage progenitors give rise to vascular endothelium.  |  Bailey, AS., et al. 2006. Proc Natl Acad Sci U S A. 103: 13156-61. PMID: 16920790
6. Myeloid suppressor cells regulate the adaptive immune response to cancer.  |  Frey, AB. 2006. J Clin Invest. 116: 2587-90. PMID: 17016554
7. Establishment, characterization and determination of cell surface sugar receptor (lectin) expression by neoglycoenzymes of a human myeloid marker-expressing B lymphoblastoid cell line.  |  Gabius, S., et al. 1991. Anticancer Res. 11: 793-800. PMID: 1712180
8. Methotrexate induced apoptotic and necrotic chromatin changes in rat myeloid leukemia cells.  |  Trencsenyi, G., et al. 2015. Inflamm Res. 64: 193-203. PMID: 25672799
9. Neuroendocrine, psychophysiological and subjective reactivity to an alcohol placebo in male alcoholic patients.  |  Dolinsky, ZS., et al. 1987. Alcohol Clin Exp Res. 11: 296-300. PMID: 3307497
10. Anti-cancer activity of guggulsterone by modulating apoptotic markers: a systematic review and meta-analysis.  |  Gupta, M., et al. 2023. Front Pharmacol. 14: 1155163. PMID: 37201024
11. Increased anti-apoptotic (Bcl-2+) and decreased proliferative (Ki-67+) cell fractions during the different maturation stages of bone marrow cell populations in MDS and AML: The potential diagnostic impact of the Bcl-2:Ki-67 ratio.  |  Mestrum, SGC., et al. 2025. Cytometry B Clin Cytom.. PMID: 40051252
12. Expression of a myeloid marker on TdT-positive acute lymphocytic leukemic cells: evidence by double-fluorescence staining.  |  Bettelheim, P., et al. 1982. Blood. 60: 1392-6. PMID: 6182933

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Apoptotic Myeloid Marker Antibody (BOB93) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-Apoptotic Myeloid Marker Antibody (BOB93) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Apoptotic Myeloid Marker Antibody (BOB93) Specifications

Alternate Product Name: Apoptotic Myeloid Marker

Product Clone Name: BOB93

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: Apoptotic Myeloid Marker

Epitope Species: human

Product Reactivity/Detection: the surface marker of all apoptotic cells

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, FCM

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for Apoptotic Myeloid Marker Antibody (BOB93): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin